https://www.selleckchem.com/products/3po.html
To investigate the influence of influence of combination with 1q21 amplification or-no in patients with newly diagnosed MM on the clinical effecacy of bortezomib-based induction chemotherapy and long-term prognosis of patients. 148 patients with newly diagnosed MM treated from January 2010 to May 2018 were selected and divided into 2 groups group A (70 patients) without 1q21 amplification and group B (78 patients) with 1q21 amplification; and the survival benefit and influence on clinical efficacy of bortezomib were compared between 2 group
Me gusta
Comentario
Compartir
